Merck publish series of Histamine H3 Receptor Inverse Agonists

Merck have publsihed a series of 2-[4-(Aminoalkoxy)phenyl]-4(3H)-quinazolinone Histamine H3 Receptor Inverse Agonists

Merck/Schering withdraw Loratadine/Montelukast NDA and Terminate Collaboration

Schering-Plough and Merck have withdrawn the NDA for the loratadine/montelukast and announced that they will terminate the joint venture which was formed to develop and market a fixed-combination product that would combine loratadine and montelukast. This follows the receipt of a not-approvable letter from the FDA in April 2008.

Somaxons low dose doxepin demonstrates efficacy in insomnia

Phase III data presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies show Somaxon’s Silenor (low dose doxepin) to demonstrate efficacy in elderly patients with insomnia.

Seroquel approved for Maintenance Treatment in Bipolar Disorder

The FDA has approved Seroquel (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder. Seroquel is already approved by the FDA for the treatment of schizophrenia

AstraZeneca submit sNDA for Seroquel XR in GAD

AstraZeneca have submitted a supplemental NDA for Seroquel XR for the Treatment of Generalised Anxiety Disorder (GAD). The drug is already launched for Bipolar disorder and Schizophrenia.

Bepreve shows beneficial effect in Ocular Allergy

ISTA Pharmaceuticals has released new Phase III clinical Findings that support is NDA Filing for Bepreve (bepotastine) for Ocular allergies